Final guidance issued on Herceptin after appeal rejected

doi:10.1136/bmj.333.7565.409

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ news articles:

From

The BMJ iPad app brings you the best of print and online, including live links to the latest news, blogs, video, and podcasts. Get the BMJ iPad app.
Countdown to London 2012: BMJ Group's Olympics portal highlights latest Olympics and sports medicine-themed research, comment and learning
Keep up to date with cardiology: Access the latest cardiovascular medicine resources from across BMJ Group.
Our online table of contents is updated at least twice each day. Read all articles published in the last 7 days.
OPEN ACCESS: All research articles are freely available online, with no word limit. Find out more about the BMJ's open access policy. Submit your paper.

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Caroline White

London

The National Institute for Health and Clinical Excellence (NICE) has issued its final guidance to English and Welsh health service trusts for the use of trastuzumab (Herceptin) for the treatment of early stage breast cancer in women with HER2 positive disease and free of heart disease.

The final guidance is based on an initial draft published earlier this year (BMJ 2006; 332: 1409). It recommends that:

Herceptin be provided at three weekly intervals for a year or until disease recurrence—whichever is sooner—after surgery, chemotherapy, and radiotherapy, if …